o Abstract: Streptococcus suis (S. suis) is a pig pathobiont that is almost ubiquitously carried in the nasopharynx. S. suis infection is most commonly associated with a previous intestinal or respiratory infection, leading to S. suis-mediated meningitis, polyarthritis, septicaemia, pneumonia and endocarditis. As a consequence, S. suis infections are a significant international animal welfare and economic burden in the pig industry. This project is expected to yield innovative and effective phage therapy solutions to specifically target S. suis in pigs. The project will use a rational design approach to generate and test phage cocktails. This design will allow the phages in the cocktail to kill a wide range of infectious S. suis strains while circumventing bacterial-mediated phage resistance, a key roadblock to the use of phage therapy (PT). Simultaneously, we will develop the Generally Regarded As Safe (GRAS) gut symbiont Lactobacillus reuteri as next-generation probiotics to deliver antimicrobials to eradicate S. suis from the pig gastrointestinal tract.